Open Payments

CEDARS-SINAI MEDICAL CENTER

Type
Teaching hospital
Where
West Hollywood, CA
Medicare CCN
050625
Received
$21,872,671 in 1,492 records, 2025 ($7,289,919 general, $14,582,751 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment317$7,289,919
2025Research payment1,175$14,582,751

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC35$2,851,9762025
Boston Scientific Corporation51$2,532,4442025
Siemens Medical Solutions USA, Inc.11$2,518,1832025
Edwards Lifesciences Corporation83$1,960,7222025
PFIZER INC.77$1,340,5102025
Genentech, Inc.37$677,8552025
Ultragenyx Pharmaceutical Inc.7$579,1652025
Janssen Research & Development, LLC68$516,9122025
Alnylam Pharmaceuticals Inc.22$515,5342025
AstraZeneca Pharmaceuticals LP16$482,9182025
E.R. Squibb & Sons, L.L.C.13$465,7242025
Genmab A/S179$416,2392025
ABBVIE INC.54$412,5642025
FUJIFILM Healthcare Americas Corporation3$321,5812025
CSL Behring11$320,1062025
Ardelyx, Inc.5$295,0002025
Medtronic, Inc.29$258,0002025
Becton, Dickinson and Company3$245,5272025
Boehringer Ingelheim Pharmaceuticals, Inc.35$228,4592025
Olympus Corporation of the Americas7$212,3342025
Regeneron Pharmaceuticals, Inc.99$204,1612025
Gilead Sciences, Inc.10$177,9902025
Eli Lilly and Company13$174,7002025
AstraZeneca UK Limited4$163,8902025
Takeda Pharmaceuticals U.S.A., Inc.39$156,7602025
Iovance Biotherapeutics, Inc.13$143,7672025
Abbott Laboratories37$125,9262025
Novocure GmbH5$124,2822025
Madrigal Pharmaceuticals13$124,0382025
BioNTech SE6$120,7242025
Jenavalve Technology, Inc.3$120,2932025
Alexion Pharmaceuticals, Inc.5$108,9462025
TG Therapeutics, Inc.3$107,1002025
W. L. Gore & Associates, Inc.7$104,6342025
Synthes GmbH10$101,5002025
Arthrex, Inc.6$97,1152025
Bolton Medical Inc8$95,5522025
Pi-Cardia, Inc.1$95,1392025
TAIHO ONCOLOGY, INC.9$94,8032025
SANOFI-AVENTIS U.S. LLC1$90,1002025
Recor Medical Inc5$83,1832025
Biosense Webster, Inc.5$80,5352025
Amgen Inc.8$77,2562025
Penumbra, Inc.21$76,2962025
M.A. Med Alliance S.A.4$72,8872025
Stryker Corporation11$70,0152025
Ionis Pharmaceuticals, Inc.12$68,6282025
Janssen Scientific Affairs, LLC4$64,9002025
Ethicon Endo-Surgery Inc.12$57,3142025
Travere Therapeutics, Inc.19$57,2862025

By nature of payment

NatureRecordsAmount
Research payment1,175$14,582,751
Grant92$3,422,153
Royalty or License15$2,430,539
Compensation for services other than consulting, including serving as faculty or as a speaker at a v37$580,639
Space rental or facility fees (teaching hospital only)93$376,710
Education14$198,834
Long term medical supply or device loan18$128,876
Charitable Contribution3$115,500
Debt forgiveness44$34,179
Honoraria1$2,488

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Merck Sharp & Dohme LLC$642,399Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2025
2025-12-31Merck Sharp & Dohme LLC$415,741Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2025
2025-12-31Merck Sharp & Dohme LLC$288,752Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase Ib/II Trial of anti-PD-1 immunotherapy and Stereotactic Radiation in Patients with Recurrent Glioblastoma2025
2025-12-31FUJIFILM Healthcare Americas Corporation$212,181Research paymentIn-kind items and servicesFUJIFILM Device, Medical DeviceProspective Registry of Shear Wave Elastography for the Pancreas using Endoscopic Ultrasound2025
2025-12-31Merck Sharp & Dohme LLC$180,119Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARA Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for 2025
2025-12-31Merck Sharp & Dohme LLC$165,780Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2025
2025-12-31Merck Sharp & Dohme LLC$153,363Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYOpen Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Combination with PARP Inhibition 2025
2025-12-31Siemens Medical Solutions USA, Inc.$145,463Research paymentIn-kind items and servicesEclipse Treatment Planning System for External Beam Radiation Therapy Device, OncologyCardiac RADIoablation versus repeat catheter Ablation: a pivotal randomized clinical Trial Evaluating safety and efficac2025
2025-12-31FUJIFILM Healthcare Americas Corporation$102,449Research paymentIn-kind items and servicesFUJIFILM Device, Medical DeviceRepository of ELUXEO Vision Endoscopic Assessment of Tissue Oxygen Saturation (StO2) Levels (REVEAL Study)2025
2025-12-31Merck Sharp & Dohme LLC$101,191Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable 2025
2025-12-31Merck Sharp & Dohme LLC$71,685Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2025
2025-12-31Merck Sharp & Dohme LLC$70,024Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants W2025
2025-12-31Merck Sharp & Dohme LLC$69,460Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable 2025
2025-12-31AngioDynamics, Inc.$44,000Long term medical supply or device loanIn-kind items and servicesNanoKnife Device, Oncology Surgery2025
2025-12-31Merck Sharp & Dohme LLC$14,701Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT2025
2025-12-31AngioDynamics, Inc.$13,000Long term medical supply or device loanIn-kind items and servicesSolero Device, Oncology2025
2025-12-31Merck Sharp & Dohme LLC$11,878Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment2025
2025-12-31Merck Sharp & Dohme LLC$10,951Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel2025
2025-12-31Merck Sharp & Dohme LLC$10,631Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2025
2025-12-31Merck Sharp & Dohme LLC$9,204Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2025
2025-12-31Stryker Corporation$6,442Long term medical supply or device loanIn-kind items and servicesSPY-PHI System Device, ENDOSCOPY2025
2025-12-31Stryker Corporation$6,353Debt forgivenessCash or cash equivalent2025
2025-12-31Merck Sharp & Dohme LLC$5,631Research paymentIn-kind items and servicesDOCETAXEL Drug, ONCOLOGYA Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resista2025
2025-12-31Stryker Corporation$4,740Long term medical supply or device loanIn-kind items and servicesBone Mill Plus Device, INSTRUMENTS2025
2025-12-31Edwards Lifesciences Corporation$4,600Research paymentCash or cash equivalentProspective, single-arm, EFS for the treatment of subjects with moderate-severe or severe symptomatic mitral valve regur2025
2025-12-31Vapotherm Inc$4,558Long term medical supply or device loanIn-kind items and servicesVAPOTHERM Device, RESPIRATORY2025
2025-12-31Merck Sharp & Dohme LLC$4,253Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2025
2025-12-31Stryker Corporation$3,808Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,716Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Merck Sharp & Dohme LLC$2,529Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as 2025
2025-12-31Stryker Corporation$1,860Long term medical supply or device loanIn-kind items and servicesSTRYKER Device, INSTRUMENTS2025
2025-12-31iRhythm Technologies, Inc.$1,775Research paymentIn-kind items and servicesZIO XT Patch Device, Cardiology/Vascular DiseasesSTUDY-CTSN PRIMARY TRIAL (CAROL-ACT)2025
2025-12-31Stryker Corporation$1,727Debt forgivenessCash or cash equivalent2025
2025-12-31Immucor, Inc.$1,310Debt forgivenessIn-kind items and services2025
2025-12-31Stryker Corporation$1,039Long term medical supply or device loanIn-kind items and servicesSPY-PHI System Device, ENDOSCOPY2025
2025-12-31Merck Sharp & Dohme LLC$997Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Phase 3, Randomized, Double-blind, Study of Belzutifan Zanzalintinib Versus Belzutifan Placebo in Participants with 2025
2025-12-31Viseon, Inc.$804Debt forgivenessIn-kind items and servicesMaxView System - Lateral Set Device, Spinal Surgery2025
2025-12-31Merck Sharp & Dohme LLC$787Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYAn Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel2025
2025-12-31Siemens Medical Solutions USA, Inc.$106Debt forgivenessIn-kind items and services2025
2025-12-31Olympus America Inc.$21Debt forgivenessIn-kind items and services Device2025
2025-12-31Thermo Fisher Scientific Asheville LLC$15Debt forgivenessCash or cash equivalent2025
2025-12-30Synthes GmbH$20,000GrantCash or cash equivalent2025
2025-12-30Synthes GmbH$6,000GrantCash or cash equivalent2025
2025-12-30Medtronic, Inc.$810Research paymentCash or cash equivalentNELLCOR Device, Pulse OximetryPulse Ox L&D Pivotal2025
2025-12-29Synthes GmbH$25,000GrantCash or cash equivalent2025
2025-12-29Janssen Research & Development, LLC$3,250Research paymentCash or cash equivalentSIMPONI Biological, ImmunologyA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-12-29Janssen Research & Development, LLC$2,127Research paymentCash or cash equivalentSIMPONI Biological, ImmunologyA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-12-29Janssen Research & Development, LLC$877Research paymentCash or cash equivalentAn Open label Multi Center Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Deli2025
2025-12-29Janssen Research & Development, LLC$455Research paymentCash or cash equivalentAn Open label Multi Center Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Deli2025
2025-12-24Daiichi Sankyo Inc.$9,287Research paymentCash or cash equivalentU31402-A-U2012025
2025-12-24United Therapeutics Corporation$5,616Research paymentCash or cash equivalentREMODULIN Drug, Pulmonary Arterial HypertensionA PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A2025
2025-12-24United Therapeutics Corporation$5,497Research paymentCash or cash equivalentREMODULIN Drug, Pulmonary Arterial HypertensionA PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A2025
2025-12-23Edwards Lifesciences Corporation$9,486Research paymentCash or cash equivalentProspective, single-arm, EFS for the treatment of subjects with moderate-severe or severe symptomatic mitral valve regur2025
2025-12-23Edwards Lifesciences Corporation$5,294Research paymentCash or cash equivalentALLIANCE 2021-052025
2025-12-22Janssen Research & Development, LLC$26,773Research paymentCash or cash equivalentA Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm2025
2025-12-22Regeneron Pharmaceuticals, Inc.$13,000Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$5,200Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$4,832Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$4,550Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$3,640Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$3,553Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22BioMarin Pharmaceutical Inc.$3,449Research paymentCash or cash equivalentVOXZOGO 1.2mg Drug, AchondroplasiaBMN 111-9022025
2025-12-22Regeneron Pharmaceuticals, Inc.$3,347Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$3,000Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$2,600Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Eidos Therapeutics, Inc.$2,210Research paymentCash or cash equivalentAttruby Drug, CardiomyopathyAn Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin 2025
2025-12-22PFIZER INC.$2,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-12-22Regeneron Pharmaceuticals, Inc.$1,878Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$1,250Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$586Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$586Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$455Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Regeneron Pharmaceuticals, Inc.$455Research paymentCash or cash equivalentA MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL 2025
2025-12-22Genmab A/S$442Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2025
2025-12-22BioMarin Pharmaceutical Inc.$325Research paymentCash or cash equivalentVOXZOGO 1.2mg Drug, AchondroplasiaBMN 111-9022025
2025-12-21FUJIFILM Healthcare Americas Corporation$6,950Space rental or facility fees (teaching hospital only)Cash or cash equivalentFUJIFILM Device, Medical Device2025
2025-12-19Regeneron Pharmaceuticals, Inc.$21,600Research paymentCash or cash equivalentMulti-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat2025
2025-12-19Regeneron Pharmaceuticals, Inc.$17,415Research paymentCash or cash equivalentMulti-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat2025
2025-12-19AstraZeneca Pharmaceuticals LP$7,792Research paymentCash or cash equivalentA Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr2025
2025-12-19Takeda Pharmaceuticals U.S.A., Inc.$7,493Research paymentCash or cash equivalentENTYVIO Biological, INTERNAL MEDICINEENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZU2025
2025-12-19Regeneron Pharmaceuticals, Inc.$5,427Research paymentCash or cash equivalentMulti-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat2025
2025-12-19Regeneron Pharmaceuticals, Inc.$3,500Research paymentCash or cash equivalentMulti-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat2025
2025-12-19Regeneron Pharmaceuticals, Inc.$3,375Research paymentCash or cash equivalentMulti-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat2025
2025-12-19Janssen Research & Development, LLC$3,010Research paymentCash or cash equivalentSIMPONI Biological, ImmunologyA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-12-19Genentech, Inc.$3,002Research paymentCash or cash equivalentPH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD2025
2025-12-19Janssen Research & Development, LLC$400Research paymentCash or cash equivalentSIMPONI Biological, ImmunologyA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-12-19Janssen Research & Development, LLC$239Research paymentCash or cash equivalentSIMPONI Biological, ImmunologyA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati2025
2025-12-19Ethicon Endo-Surgery Inc.$194Research paymentCash or cash equivalentNeuwave Device, Ablation SystemA Multi Center Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue2025
2025-12-18Boston Scientific Corporation$35,000GrantCash or cash equivalentGeneral - Tachy Device, General - Tachy_CRM2025
2025-12-18Recor Medical Inc$8,385Research paymentCash or cash equivalentParadise Ultrasound Renal Denervation System Device, DevicesRADIANCE CAP2025
2025-12-18Boston Scientific Corporation$6,950GrantIn-kind items and servicesGeneral - Tachy Device, General - Tachy_CRM2025
2025-12-18Recor Medical Inc$2,470Research paymentCash or cash equivalentParadise Ultrasound Renal Denervation System Device, DevicesRADIANCE CAP2025
2025-12-18Travere Therapeutics, Inc.$845Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2025
2025-12-17Merck Sharp & Dohme LLC$186,826Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w2025
2025-12-17Novocure GmbH$54,881Research paymentCash or cash equivalentEF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat2025
2025-12-17Synthes GmbH$7,500GrantCash or cash equivalent2025
2025-12-17Novocure GmbH$4,550Research paymentCash or cash equivalentEF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat2025
2025-12-17Olympus Corporation of the Americas$4,000GrantIn-kind items and servicesEVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology2025
2025-12-16Boston Scientific Corporation$11,550Research paymentCash or cash equivalentVercise Device, Vercise_NMDUS DBS REGISTRY2025
2025-12-16Premia Spine, Ltd.$4,160Research paymentCash or cash equivalentTOPSA Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System2025
2025-12-16Boehringer Ingelheim Pharmaceuticals, Inc.$3,300Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-12-16Boston Scientific Corporation$1,034Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIELEGANCE2025
2025-12-16Madrigal Pharmaceuticals$130Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL2025
2025-12-16Boston Scientific Corporation$13Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICACURATE IDE2025
2025-12-15Merck Sharp & Dohme LLC$80,310Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYAn Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel2025
2025-12-15Olympus Corporation of the Americas$20,000GrantCash or cash equivalent2025
2025-12-15Edwards Lifesciences Corporation$1,820Research paymentCash or cash equivalentALTERRA Early Feasibility (2016-04)2025
2025-12-15Edwards Lifesciences Corporation$1,241Research paymentCash or cash equivalentJOURNEY (Trial JCM-002)2025
2025-12-12Genentech, Inc.$11,886Research paymentCash or cash equivalentPH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD2025
2025-12-12Stryker Corporation$5,000GrantCash or cash equivalent2025
2025-12-12Medtronic, Inc.$2,785Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2025
2025-12-12Lexicon Pharmaceuticals, Inc.$2,202Research paymentCash or cash equivalentSONATA-HCM2025
2025-12-12Gilead Sciences, Inc.$780Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien2025
2025-12-11Boston Scientific Corporation$2,137,452GrantIn-kind items and servicesGeneral - Tachy Device, General - Tachy_CRM2025
2025-12-11Edwards Lifesciences Corporation$6,607Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012025
2025-12-11PFIZER INC.$3,167Research paymentCash or cash equivalentA LOWINTERVENTIONAL STUDY TO ASSESS PHYSICAL ACTIVITY USING DIGITAL HEALTH TECHNOLOGY IN ADULT PARTICIPANTS WITH CACHEXI2025
2025-12-11Janssen Research & Development, LLC$2,400Research paymentCash or cash equivalentREMICADE Biological, ImmunologyA Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEV2025
2025-12-11Edwards Lifesciences Corporation$2,276Research paymentCash or cash equivalentALTERRA Post-Approval Study 2021-112025
2025-12-10Edwards Lifesciences Corporation$176,599Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-12-10Edwards Lifesciences Corporation$71,283Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2025
2025-12-10Merck Sharp & Dohme LLC$42,749Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYA Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma2025
2025-12-10Ionis Pharmaceuticals, Inc.$25,650Research paymentCash or cash equivalentION582P32025
2025-12-10Vapotherm Inc$24,220Long term medical supply or device loanIn-kind items and servicesVAPOTHERM Device, RESPIRATORY2025
2025-12-10Gilead Sciences, Inc.$19,110Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien2025
2025-12-10Cook Incorporated$5,000GrantCash or cash equivalent2025
2025-12-10Gilead Sciences, Inc.$3,500Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien2025
2025-12-10Ionis Pharmaceuticals, Inc.$3,000Research paymentCash or cash equivalentION582P32025
2025-12-10Ionis Pharmaceuticals, Inc.$2,700Research paymentCash or cash equivalentION582P32025
2025-12-10Abbott Laboratories$2,650Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-12-10Abbott Laboratories$1,950Research paymentCash or cash equivalent Device, Structural HeartNCT06223789--VOLT-AF IDE Clinical Study2025
2025-12-10Gilead Sciences, Inc.$1,950Research paymentCash or cash equivalentLivdelzi Drug, INFLAMA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien2025
2025-12-10Mannkind Corporation$650Research paymentCash or cash equivalentICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION2025
2025-12-10Sumitomo Pharma America, Inc.$1Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-09Gilead Sciences, Inc.$100,000GrantCash or cash equivalent2025
2025-12-09PFIZER INC.$57,300Research paymentIn-kind items and servicesAN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO2025
2025-12-09Takeda Pharmaceuticals U.S.A., Inc.$11,676Research paymentCash or cash equivalentVPRIV Biological, GENETIC DISEASEGAUCHER DISEASE OUTCOME SURVEY (GOS) AN OBSERVATIONAL, INTERNATIONAL, MULTICENTER, LONG-TERM REGISTRY OF PATIENTS WITH G2025
2025-12-09Medical Device Business Services, Inc.$10,000GrantCash or cash equivalent2025
2025-12-09COLOPLAST CORP$2,774Research paymentCash or cash equivalentINTIBIA2025
2025-12-09Boston Scientific Corporation$1,005Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICAGENT IDE2025
2025-12-09PFIZER INC.$7Research paymentIn-kind items and servicesAN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO2025
2025-12-08Ultragenyx Pharmaceutical Inc.$80,840Research paymentCash or cash equivalentGTX-102-CL3012025
2025-12-08SANOFI US SERVICES INC.$37,912Research paymentCash or cash equivalentA Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safet2025
2025-12-08PFIZER INC.$34,651Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and services2025
2025-12-08Ascendis Pharma Endocrinology Inc$5,642Research paymentCash or cash equivalentIL Believe2025
2025-12-08PFIZER INC.$1,750Research paymentCash or cash equivalentXTANDI Drug, ONCOLOGYA RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA2025
2025-12-08Penumbra, Inc.$358Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2025
2025-12-08ABBVIE INC.$200Research paymentCash or cash equivalentStudy Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa2025
2025-12-04ABBVIE INC.$15,634Research paymentCash or cash equivalentStudy Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa2025
2025-12-04Janssen Research & Development, LLC$5,134Research paymentCash or cash equivalentA Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm2025
2025-12-03Merck Sharp & Dohme LLC$64,980Research paymentCash or cash equivalentWELIREG Drug, ONCOLOGYA Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants W2025
2025-12-03Arthrex, Inc.$40,000Research paymentCash or cash equivalentBiomechanical Analysis of SuturePatch Augmentation of Soft-Tissue Repair2025
2025-12-03CSL Behring$20,550Research paymentCash or cash equivalentA Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom2025
2025-12-03Bolton Medical Inc$17,142Research paymentCash or cash equivalentTHORAFLEX HYBRID Device, ENDOVASCULAR AORTIC REPAIREXTEND2025
2025-12-03Boehringer Ingelheim Pharmaceuticals, Inc.$8,549Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-12-03CSL Behring$3,500Research paymentCash or cash equivalentA Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom2025
2025-12-03Boehringer Ingelheim Pharmaceuticals, Inc.$1,560Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-12-03Sumitomo Pharma America, Inc.$267Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$228Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$220Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$158Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$105Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$99Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$99Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$89Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$79Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$64Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$6Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$5Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$4Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-03Sumitomo Pharma America, Inc.$2Research paymentIn-kind items and servicesAN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS2025
2025-12-02Madrigal Pharmaceuticals$17,247Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL2025
2025-12-02Cochlear Americas$15Debt forgivenessCash or cash equivalentCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2025
2025-12-01Takeda Pharmaceuticals U.S.A., Inc.$3,967Research paymentCash or cash equivalentAn Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy with Vedolizumab Intravenous (2025
2025-12-01Travere Therapeutics, Inc.$3,924Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2025
2025-12-01Takeda Pharmaceuticals U.S.A., Inc.$2,531Research paymentCash or cash equivalentVedolizumab-4054 A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)2025
2025-11-28Edwards Lifesciences Corporation$7,500Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012025
2025-11-28Boston Scientific Corporation$2,995GrantIn-kind items and servicesGeneral - Tachy Device, General - Tachy_CRM2025
2025-11-28Edwards Lifesciences Corporation$2,346Research paymentCash or cash equivalentSM3 Trial 2017-032025
2025-11-28Edwards Lifesciences Corporation$234Research paymentCash or cash equivalentCOMPASSION S3 Post Approval Study (2020-07)2025
2025-11-27Janssen Research & Development, LLC$2,895Research paymentCash or cash equivalentA Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm2025
2025-11-26E.R. Squibb & Sons, L.L.C.$35,130Research paymentCash or cash equivalentA Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors2025
2025-11-26Orthofix Medical, Inc.$4,802Research paymentCash or cash equivalentFBBT, HPCS, OPHR2025
2025-11-26PFIZER INC.$1,233Research paymentCash or cash equivalentA LOWINTERVENTIONAL STUDY TO ASSESS PHYSICAL ACTIVITY USING DIGITAL HEALTH TECHNOLOGY IN ADULT PARTICIPANTS WITH CACHEXI2025
2025-11-25KLS-Martin L.P.$547Debt forgivenessCash or cash equivalentLEVEL ONE, CLAMP, REDUCTION, BONE, SHARP, 15 CM, QTY: 001 EA Device, Osteosynthesis2025
2025-11-24CSL Behring$2,985Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-11-24Integra LifeSciences Corporation$1,000GrantCash or cash equivalent2025
2025-11-24PFIZER INC.$15Research paymentIn-kind items and servicesAN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO2025
2025-11-21Genmab A/S$2,830Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2025
2025-11-21GENZYME CORPORATION$2,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentCERDELGA Drug, Genetic Disease2025
2025-11-21Eidos Therapeutics, Inc.$323Research paymentCash or cash equivalentAttruby Drug, CardiomyopathyAn Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin 2025
2025-11-20Arthrex, Inc.$7,500GrantCash or cash equivalent2025
2025-11-20ABBVIE INC.$6,725Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYA Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric P2025
2025-11-20Globus Medical, Inc.$3,000GrantCash or cash equivalent2025
2025-11-20CSL Behring$105Research paymentIn-kind items and servicesA Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom2025
2025-11-19PFIZER INC.$46,207Research paymentIn-kind items and servicesXTANDI Drug, ONCOLOGYA PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS2025
2025-11-19Musculoskeletal Transplant Foundation Inc.$3,839Research paymentCash or cash equivalentIPA The Effect of Reticular Meshed Dermal ALlograft on Wound Healing2025
2025-11-19Abbott Laboratories$1,467Research paymentCash or cash equivalentPORTICO Device, Structural HeartNCT04011722--Portico Next Generation Approval Study2025
2025-11-19PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025

The latest 200 records of 1,492.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Los Angeles CountyWest Hollywood city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In West Hollywood, CA, county Los Angeles County, CA, state California; placed by its city name.

MeasurePlace (city or town)
West Hollywood, CA
County
Los Angeles County, CA
State
California
Population B0100334,8849,808,66739,287,377
Population, 2020 census P135,75710,014,00939,538,223
Median age B0100240.038.237.9
Under 18 B010013.6%20.6%22.0%
65 and over B0100116.8%15.2%15.7%
Households B1100122,9203,416,44913,548,091
Foreign born B0500223.6%33.4%27.0%
Median household income B19013$96,995$90,112$99,122
Median family income B19113$126,364$101,573$113,346
Per capita income B19301$90,080$45,792$49,513
Poverty rate B1700112.9%13.7%12.0%
Unemployment rate B230258.9%7.3%6.6%
Civilian labor force B2302525,8185,200,65620,068,466
Mean commute (minutes) B0801327.130.428.7
Bachelor's degree or higher B1500364.2%36.0%37.1%
Housing units B2500126,0793,650,46614,644,735
Owner-occupied B2500319.8%45.9%55.9%
Renters B2500380.2%54.1%44.1%
Median home value B25077$924,800$834,200$734,700
Median gross rent B25064$2,091$1,954$2,036
White, not Hispanic B0300269.5%24.7%33.8%
Black B030024.3%7.4%5.2%
Hispanic or Latino B0300213.1%48.4%40.2%
Asian B030026.1%14.9%15.3%
American Indian and Alaska Native B030020.1%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in West Hollywood, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.